Transaction DateRecipientSharesTypePriceValue
23rd November 2020Ventures Fund Iv General Partner Llc Flagship642,180Other acquisition or disposition$0.00
23rd November 2020Ventures Fund Iv General Partner Llc Flagship43,154Other acquisition or disposition$0.00
23rd November 2020Ventures Fund Iv General Partner Llc Flagship1,481,481Other acquisition or disposition$0.00
23rd November 2020Ventures Fund Iv General Partner Llc Flagship966,234Other acquisition or disposition$0.00
23rd November 2020Ventures Fund Iv General Partner Llc Flagship1,186,310Other acquisition or disposition$0.00
23rd November 2020Ventures Fund Iv General Partner Llc Flagship3,587,820Other acquisition or disposition$0.00
2nd September 2020James R Tobin5,600Open or private sale$56.85$318,360.00
2nd September 2020James R Tobin5,600Exercise of derivative$26.27$147,112.00
1st September 2020John F Carey2,000Exercise of derivative$0.39$780.00
1st September 2020John F Carey2,000Open or private sale$17.59$35,180.00
Trans Medics Group
Trans Medics Group logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


TransMedics Group, Inc. focuses on the preservation of human organs for transplant in a near-physiologic condition. The company was founded by Waleed H. Hassanein in October 2018.


Ticker: TMDX
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1756262
Employees: 109
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals